Utilisation of the ESMO-MCBS in practice of HTA.

Wild, C; Grössmann, N; Bonanno, P V; Bucsics, A; Furst, J; Garuoliene, K; Godman, B; Gulbinovic, J; Jones, J; Pomorski, M K; Emprechtinger, R

Wild, C; Grössmann, N; Bonanno, P V; Bucsics, A; Furst, J; Garuoliene, K; Godman, B; Gulbinovic, J; Jones, J; Pomorski, M K; Emprechtinger, R.

Affiliation

Wild C; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria claudia.wild@hta.lbg.ac.at.
Grössmann N; Ludwig Boltzmann Institute for Health Technology Assessment (LBI-HTA), Vienna, Austria.
Bonanno PV; Independent Pharmaceutical Consultant, Mellieha, Malta.
Bucsics A; Department of Finance, University of Vienna, Austria.
Furst J; Medicinal Products Department, Health Insurance Institute of Slovenia, Ljubljana, Slovenia.
Garuoliene K; Medicines Reimbursement Department, National Health Insurance Fund, Vilnius, Lithuania.
Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK.
Gulbinovic J; Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden.
Jones J; Faculty of Medicine, Department of Pathology, Forensic Medicine and Pharmacology, Vilnius University and State Medicines Control Agency, Vilnius, Lithuania.
Pomorski MK; Healthcare Improvement Scotland, Scottish Medicine Consortium, Glasgow, UK.
Emprechtinger R; Agency for Health Technology Assessment and Tariff System, Warsaw, Poland.

Ann Oncol ; 27(11): 2134-2136, 2016 11.

Article in En | MEDLINE | ID: mdl-27502718

Subject(s)

Medical Oncology; Technology Assessment, Biomedical; Humans

Search on Google

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Technology Assessment, Biomedical / Medical Oncology Type of study: Health_technology_assessment Limits: Humans Language: En Journal: Ann Oncol Year: 2016 Document type: Article

Search on Google

XML

PubMed Links